JP2006527208A - 抗腫瘍活性を有するポリエンオキサゾール、及びストレプトミセス株を使用するその調製方法 - Google Patents

抗腫瘍活性を有するポリエンオキサゾール、及びストレプトミセス株を使用するその調製方法 Download PDF

Info

Publication number
JP2006527208A
JP2006527208A JP2006515591A JP2006515591A JP2006527208A JP 2006527208 A JP2006527208 A JP 2006527208A JP 2006515591 A JP2006515591 A JP 2006515591A JP 2006515591 A JP2006515591 A JP 2006515591A JP 2006527208 A JP2006527208 A JP 2006527208A
Authority
JP
Japan
Prior art keywords
compound
cancer cells
pharmaceutically acceptable
growth
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006515591A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006527208A5 (enExample
Inventor
ジェイムス ビー ムカルピン
クリス エム ファーネット
エマヌエル ザゾプロス
ナルギス イズメイル
ブライアン オー バックマン
Original Assignee
エコピア バイオサイエンシーズ インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エコピア バイオサイエンシーズ インク filed Critical エコピア バイオサイエンシーズ インク
Publication of JP2006527208A publication Critical patent/JP2006527208A/ja
Publication of JP2006527208A5 publication Critical patent/JP2006527208A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/14—Nitrogen or oxygen as hetero atom and at least one other diverse hetero ring atom in the same ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • C12R2001/60—Streptomyces sparsogenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2006515591A 2003-06-13 2004-06-14 抗腫瘍活性を有するポリエンオキサゾール、及びストレプトミセス株を使用するその調製方法 Pending JP2006527208A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47793103P 2003-06-13 2003-06-13
PCT/CA2004/000872 WO2004110439A1 (en) 2003-06-13 2004-06-14 Polyene oxazoles with antitumour activity and processes for their preparation using a streptomyces strain

Publications (2)

Publication Number Publication Date
JP2006527208A true JP2006527208A (ja) 2006-11-30
JP2006527208A5 JP2006527208A5 (enExample) 2007-07-12

Family

ID=33551785

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006515591A Pending JP2006527208A (ja) 2003-06-13 2004-06-14 抗腫瘍活性を有するポリエンオキサゾール、及びストレプトミセス株を使用するその調製方法

Country Status (7)

Country Link
US (2) US7312339B2 (enExample)
EP (1) EP1633352B1 (enExample)
JP (1) JP2006527208A (enExample)
AT (1) ATE344032T1 (enExample)
CA (1) CA2470935A1 (enExample)
DE (1) DE602004003056D1 (enExample)
WO (1) WO2004110439A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112067647A (zh) * 2020-11-11 2020-12-11 东南大学 一种检测液体生物样本葡萄糖含量的弛豫核磁共振方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2512240T3 (es) * 2009-07-14 2014-10-23 Takasago International Corporation Método para preparar espilantol y producto intermedio para su preparación
CN107478670B (zh) * 2017-08-08 2018-04-03 中国环境科学研究院 一种沉积物中肌醇磷酸盐与腐殖酸相互作用的分析方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3364198A (en) * 1964-10-12 1968-01-16 Upjohn Co Process for the production of n6-methyltubercidin and intermediate
JPS6081184A (ja) * 1983-10-11 1985-05-09 Banyu Pharmaceut Co Ltd 抗腫瘍性抗生物質及びその製法
JPS61172881A (ja) * 1985-01-26 1986-08-04 Meiji Seika Kaisha Ltd 新抗生物質キューロマイシンａ又はｂとその製造法
JPH08176116A (ja) * 1994-12-27 1996-07-09 Rikagaku Kenkyusho 新規抗生物質スパロキソマイシン

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5039660A (en) 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
JP2003514033A (ja) * 1999-11-15 2003-04-15 パーカー ヒューズ インスティテュート 癌治療用のホルボキサゾール誘導体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3364198A (en) * 1964-10-12 1968-01-16 Upjohn Co Process for the production of n6-methyltubercidin and intermediate
JPS6081184A (ja) * 1983-10-11 1985-05-09 Banyu Pharmaceut Co Ltd 抗腫瘍性抗生物質及びその製法
JPS61172881A (ja) * 1985-01-26 1986-08-04 Meiji Seika Kaisha Ltd 新抗生物質キューロマイシンａ又はｂとその製造法
JPH08176116A (ja) * 1994-12-27 1996-07-09 Rikagaku Kenkyusho 新規抗生物質スパロキソマイシン

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112067647A (zh) * 2020-11-11 2020-12-11 东南大学 一种检测液体生物样本葡萄糖含量的弛豫核磁共振方法
CN112067647B (zh) * 2020-11-11 2021-01-15 东南大学 一种检测液体生物样本葡萄糖含量的弛豫核磁共振方法

Also Published As

Publication number Publication date
EP1633352A1 (en) 2006-03-15
DE602004003056D1 (de) 2006-12-14
WO2004110439A1 (en) 2004-12-23
US7312339B2 (en) 2007-12-25
US20090069396A1 (en) 2009-03-12
ATE344032T1 (de) 2006-11-15
CA2470935A1 (en) 2004-12-13
US20050038090A1 (en) 2005-02-17
EP1633352B1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
KR20020092899A (ko) 항생 물질 카프라자마이신류 및 그 제조법
US20090069396A1 (en) Polyene Oxazoles and Processes for Their Preparation
JP3715651B2 (ja) 抗腫瘍イソクマリン類
JPWO2005061461A1 (ja) ヒートショックプロテイン９０（ｈｓｐ９０）ファミリー蛋白質阻害剤
WO2002072617A1 (en) Thiopeptide compounds
JP2006528664A (ja) ポリエンポリケチド、その調製方法及び医薬品としてのその使用
JP2013542173A (ja) 新規抗菌性化合物、それらの作製法、およびそれらの使用
US4772595A (en) Synthetic virginiamycin M1 analogs
US4859690A (en) Therapeutic virginiamycin M1 analogs
US5334613A (en) Antibacterial substance BE-24566B
US5137900A (en) Therapeutic virginiamycin M1 analogs
CA1279278C (en) Fermentation analogs of virginiamycin m1
HUP0102370A2 (hu) Mumbaisztatin, eljárás előállítására és alkalmazása gyógyszerhatóanyagként
JP3851661B2 (ja) 新規生理活性物質及びその製造方法
CN104418833B (zh) 抗霉素类似物及其制备方法和用途
US4894370A (en) Compositions having fermentation analogs of virginiamycin M1 as active ingredient
JPWO1997043434A1 (ja) 新規生理活性物質及びその製造方法
JPH0558440B2 (enExample)
HUT63883A (en) Physiologically active kanglemycin c, process for producing and using same
WO2006073151A1 (ja) 新規発酵生産物
JPS62174040A (ja) ３”−ヒドロキシ−ｍｌ−２３６ｂ誘導体およびその製造法
JP2006213704A (ja) 新規発酵生産物
JP2006213703A (ja) 新規発酵生産物
JP2008074710A (ja) 新規ａ−９７０６５類物質
JPWO1998056809A1 (ja) 生理活性物質ポリオキシペプチンおよびデオキシポリオキシペプチンとそれを含む抗癌剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070523

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20090729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100804

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100906

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100913

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101209